Paul Tudor Jones’s Alnylam Pharmaceuticals ALNY Stock Holding History

Paul Tudor Jones’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,800	Closed	-$596K	–	3497
2026 Q1	$596K	Buy	+1,800	New	+$613K	﹤0.01%	2701
2025 Q4	–	Sell	-2,500	Closed	-$1.14M	–	3451
2025 Q3	$1.14M	Buy	+2,500	New	+$1.02M	﹤0.01%	2170
2025 Q2	–	Sell	-1,300	Closed	-$351K	–	3198
2025 Q1	$351K	Sell	1,300 -13,000	-91%	-$3.34M	﹤0.01%	2500
2024 Q4	$3.36M	Buy	14,300 +1,700	+13%	+$447K	0.01%	914
2024 Q3	$3.47M	Buy	+12,600	New	+$3.28M	0.01%	894

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's ALNY Position: Q4 2024 in Review

Paul Tudor Jones sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 3,386 shares — an estimated $890K sold.

Paul Tudor Jones first reported a position in ALNY in Q4 2014 and held it in 14 quarters. The position peaked at $14.7M in Q2 2024. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Paul Tudor Jones reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Paul Tudor Jones sold 3,386 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $890K.
Paul Tudor Jones first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 14 quarters.
Paul Tudor Jones's Alnylam Pharmaceuticals position peaked at $14.7M in Q2 2024.
594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.